Amgen Inc (AMGN)
298.41
-12.88
(-4.14%)
USD |
NASDAQ |
May 06, 11:59
Amgen SG&A Expense (TTM): 6.729B for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 6.729B |
December 31, 2023 | 6.179B |
September 30, 2023 | 5.477B |
June 30, 2023 | 5.411B |
March 31, 2023 | 5.444B |
December 31, 2022 | 5.414B |
September 30, 2022 | 5.267B |
June 30, 2022 | 5.285B |
March 31, 2022 | 5.342B |
December 31, 2021 | 5.368B |
September 30, 2021 | 5.716B |
June 30, 2021 | 5.757B |
March 31, 2021 | 5.668B |
December 31, 2020 | 5.73B |
September 30, 2020 | 5.47B |
June 30, 2020 | 5.347B |
March 31, 2020 | 5.312B |
December 31, 2019 | 5.15B |
September 30, 2019 | 5.196B |
June 30, 2019 | 5.266B |
March 31, 2019 | 5.359B |
December 31, 2018 | 5.332B |
September 30, 2018 | 5.20B |
June 30, 2018 | 5.077B |
March 31, 2018 | 4.933B |
Date | Value |
---|---|
December 31, 2017 | 4.87B |
September 30, 2017 | 4.766B |
June 30, 2017 | 4.84B |
March 31, 2017 | 4.923B |
December 31, 2016 | 5.062B |
September 30, 2016 | 5.155B |
June 30, 2016 | 5.155B |
March 31, 2016 | 5.023B |
December 31, 2015 | 4.846B |
September 30, 2015 | 4.757B |
June 30, 2015 | 4.726B |
March 31, 2015 | 4.702B |
December 31, 2014 | 4.699B |
September 30, 2014 | 4.893B |
June 30, 2014 | 4.929B |
March 31, 2014 | 5.049B |
December 31, 2013 | 5.184B |
September 30, 2013 | 5.036B |
June 30, 2013 | 4.918B |
March 31, 2013 | 4.893B |
December 31, 2012 | 4.814B |
September 30, 2012 | 4.662B |
June 30, 2012 | 4.656B |
March 31, 2012 | 4.555B |
December 31, 2011 | 4.499B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
5.15B
Minimum
Dec 2019
6.729B
Maximum
Mar 2024
5.526B
Average
5.412B
Median
SG&A Expense (TTM) Benchmarks
Gilead Sciences Inc | 6.147B |
Johnson & Johnson | 21.93B |
Eli Lilly and Co | 6.912B |
Merck & Co Inc | 10.51B |
Vertex Pharmaceuticals Inc | 1.137B |